The lifeblood of collaborative research at UAB is an Institutional Center infrastructure that embodies comfortable coexistence among strong Departments and Center organizations. Over the past few years, interdisciplinary approaches to CF science have blossomed at our institution from a focus on cellular, molecular and translational aspects of the disease. Very recently, with a concerted emphasis on translational science, UAB has positioned itself as an emerging leader in CF patient oriented research. The richness of CF cellular biology at UAB has grown in parallel with this clinical and translational expansion. A P30 CF Core Center in Birmingham will propel investigators at UAB and collaborating sites towards improved understanding of the most basic underpinnings of cystic fibrosis pathogenesis, and the ways this information can be aggressively applied to experimental therapeutics. This UAB P30 includes three Scientific Cores to help organize efforts of CF faculty towards this common and essential goal. These include: Core A: Cell Model and Assay Core (KL Kirk, PI);Core B: Mouse Models Core (DM Bedwell, PI);and Core C: Clinical Core (JP Clancy, PI). Each Core will provide leading edge assays, specialized reagents and sound experimental expertise. The Center has also recruited new investigators through a Pilot and Feasibility mechanism integral to Center prosperity. In addition to providing a platform from which new junior and senior scientists can be brought into the field, Pilot Projects serve as a means of rapidly testing exciting advances, particularly from the perspective of clinical translation. Three Pilot and Feasibility Projects are proposed: Project 1: SM Rowe, PI. Role of Flavonoids in CFTR Biogenesis and Activation;Project 2: G Liu, PI. Mechanisms and Therapeutic Implications of HMGB1 in CF Lung Inflammation;Project 3: L Gerald, PI. The Relationship Between Health Literacy, Treatment Adherence, and Outcomes in CF. The UAB CF and Translation Core Center will consolidate and accelerate a large number of CF research programs locally and nationally. Progress will be measured by important new contributions and scientific discovery designed to improve the lives of patients with CF.
| Shei, Ren-Jay; Peabody, Jacelyn E; Kaza, Niroop et al. (2018) The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis. Curr Opin Pharmacol 43:152-165 |
| Gebert, Magdalena; Bartoszewska, Sylwia; Janaszak-Jasiecka, Anna et al. (2018) PIWI proteins contribute to apoptosis during the UPR in human airway epithelial cells. Sci Rep 8:16431 |
| Montoro, Daniel T; Haber, Adam L; Biton, Moshe et al. (2018) A revised airway epithelial hierarchy includes CFTR-expressing ionocytes. Nature 560:319-324 |
| Lutful Kabir, Farruk; Ambalavanan, Namasivayam; Liu, Gang et al. (2018) MicroRNA-145 Antagonism Reverses TGF-? Inhibition of F508del CFTR Correction in Airway Epithelia. Am J Respir Crit Care Med 197:632-643 |
| Shei, Ren-Jay; Peabody, Jacelyn E; Rowe, Steven M (2018) Functional Anatomic Imaging of the Airway Surface. Ann Am Thorac Soc 15:S177-S183 |
| Clancy, John Paul; Cotton, Calvin U; Donaldson, Scott H et al. (2018) CFTR modulator theratyping: Current status, gaps and future directions. J Cyst Fibros : |
| Plyler, Z E; Birket, S E; Schultz, B D et al. (2018) Non-obstructive vas deferens and epididymis loss in cystic fibrosis rats. Mech Dev : |
| Poore, T Spencer; Virella-Lowell, Isabel; Guimbellot, Jennifer S (2018) Potential pathogenicity of Inquilinus limosus in a pediatric patient with cystic fibrosis. Pediatr Pulmonol 53:E21-E23 |
| Heltshe, Sonya L; Rowe, Steven M; Skalland, Michelle et al. (2018) Ivacaftor-treated Patients with Cystic Fibrosis Derive Long-Term Benefit Despite No Short-Term Clinical Improvement. Am J Respir Crit Care Med 197:1483-1486 |
| Guimbellot, Jennifer; Solomon, George M; Baines, Arthur et al. (2018) Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations. J Cyst Fibros : |
Showing the most recent 10 out of 175 publications
